Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 + Sintilimab in Advanced Gastric/GEJ Adenocarcinoma
NCT06321913Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of arcotatug tavatecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Harbin Medical University. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06321913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321913.